Senti Biosciences Company Top Insiders
SNTI Stock | USD 5.48 0.14 2.49% |
Senti Biosciences employs about 48 people. The company is managed by 11 executives with a total tenure of roughly 112 years, averaging almost 10.0 years of service per executive, having 4.36 employees per reported executive. Assessment of Senti Biosciences' management performance can provide insight into the firm performance.
Senti |
Senti Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.3302) % which means that it has lost $0.3302 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1107) %, meaning that it created substantial loss on money invested by shareholders. Senti Biosciences' management efficiency ratios could be used to measure how well Senti Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.82. The current Return On Capital Employed is estimated to decrease to -0.91. As of now, Senti Biosciences' Net Tangible Assets are increasing as compared to previous years. The Senti Biosciences' current Non Currrent Assets Other is estimated to increase to about 2.1 M, while Total Assets are projected to decrease to under 105.9 M.The Senti Biosciences' current Common Stock Shares Outstanding is estimated to increase to about 4.7 M, while Net Loss is projected to decrease to (55 M).
Senti Biosciences Workforce Comparison
Senti Biosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 685. Senti Biosciences holds roughly 48.0 in number of employees claiming about 7% of equities under Health Care industry.
Senti Biosciences Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Senti Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Senti Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Senti Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2022-06-01 | 0.087 | 2 | 23 | 362,519 | 27,166,834 |
2014-06-01 | 7.0 | 14 | 2 | 2,500,672 | 544,959 |
Senti Biosciences Notable Stakeholders
A Senti Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Senti Biosciences often face trade-offs trying to please all of them. Senti Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Senti Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Kanya MD | Head President | Profile | |
Yvonne MBA | Treasurer CFO | Profile | |
Susan Berland | Senior Director | Profile | |
Dee Dragon | Vice Culture | Profile | |
Thomas Chung | Vice Development | Profile | |
Susan Kahlert | Controller | Profile | |
James Collins | Chairperson CoFounder | Profile | |
Wilson Wong | Scientific Board | Profile | |
Deborah Knobelman | CFO Treasurer | Profile | |
Philip Lee | CoFounder CTO | Profile | |
Mike Rhee | General Secretary | Profile |
About Senti Biosciences Management Performance
The success or failure of an entity such as Senti Biosciences often depends on how effective the management is. Senti Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Senti management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Senti management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.78) | (0.82) | |
Return On Capital Employed | (0.87) | (0.91) | |
Return On Assets | (0.78) | (0.82) | |
Return On Equity | (1.39) | (1.32) |
Senti Biosciences Workforce Analysis
Traditionally, organizations such as Senti Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Senti Biosciences within its industry.Senti Biosciences Manpower Efficiency
Return on Senti Biosciences Manpower
Revenue Per Employee | 53.4K | |
Revenue Per Executive | 232.8K | |
Net Loss Per Employee | 1.5M | |
Net Loss Per Executive | 6.5M | |
Working Capital Per Employee | 1.2M | |
Working Capital Per Executive | 5.3M |
Complementary Tools for Senti Stock analysis
When running Senti Biosciences' price analysis, check to measure Senti Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Senti Biosciences is operating at the current time. Most of Senti Biosciences' value examination focuses on studying past and present price action to predict the probability of Senti Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Senti Biosciences' price. Additionally, you may evaluate how the addition of Senti Biosciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |